We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Study Results Validate Use of Tumor Markers to Treat Metastatic Cancer

By LabMedica International staff writers
Posted on 17 Jun 2019
Promising results obtained in a recently conducted pilot study demonstrated the feasibility of using molecular tumor markers as the basis for selecting the chemotherapeutic agents to use in patients with metastatic pancreatic cancer.

Investigators at Georgetown University (Washington, DC, USA) and collaborators at several other institutions carried out a study designed to assess the feasibility of following a treatment algorithm based on the expression of three published predictive markers of response to chemotherapy: ribonucleotide reductase catalytic subunit M1 (for gemcitabine); excision repair cross-complementation group 1 (for platinum agents); and thymidylate synthase (for 5-fluorouracil) in patients with untreated, metastatic pancreatic cancer.

Initially, 30 patients were enrolled in the study. More...
However, 10 patients failed screening primarily due to inadequate tumor tissue availability. Of the remaining 20 patients, tumor biopsy analysis was used to assign them to one of seven doublet treatment regimens. Key secondary objectives included response rate (RR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).

Results revealed promising indications for progression-free survival and overall survival, with a partial response seen in 28% of patients and stable disease in 50% by completion of the study.

Based on the results from this pilot study, a larger phase II randomized trial of molecularly targeted therapy versus physicians' choice of standard of care has been initiated.

Results of the pilot study were discussed in the May 2, 2019, online edition of the Journal of Pancreatic Cancer.

Related Links:
Georgetown University


New
Gold Member
Hybrid Pipette
SWITCH
Collection and Transport System
PurSafe Plus®
Human Estradiol Assay
Human Estradiol CLIA Kit
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.